Tag: 定量的システム薬理学 (QSP)
Gene Therapy Virtual Twin Platformを活用した投与量の最適化
This blog explains how using the Gene Therapy Virtual Twin™ Platform can help optimize dosing for patients.
Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm
Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno‐oncology (IO) the aim is to direct the patient’s own immune system to fight cancer. After remarkable successes of antibodies targeting PD1/PD‐L1 and CTLA4 receptors in targeted patient populations, the focus of further development … Continued
Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology
Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat cancer. In addition to clinically validated immune cell re‐targeting, bsAbs are being designed for tumor targeting and as dual immune modulators. Explorative preclinical and emerging clinical data indicate potential for enhanced efficacy and reduced systemic toxicity. However, bsAbs are a … Continued
Accelerating Vaccine Development: Applications to COVID-19 and Future Pandemics
Simcyp：20年に渡るイノベーションの軌跡
The consortium members have partnered with Simcyp and Certara during the past 20 years to advance the science of drug development through modeling & simulation
Mechanistic models of cancer Mechanistic models cancer-immune cycle and immunotherapies
Optimize Immuno-oncology Drug Discovery and Development Using QSP
A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to better predict effective drug combinations, especially to more accurately correlate the physiological differences between preclinical models and human patients.
腫瘍薬開発と患者アクセスの枠組みを変革する
Maximize your understanding of your anti-cancer drug’s safety and efficacy profile to achieve regulatory and commercial success with Certara’s strategic and technology-enabled services across the entire drug development continuum – from pre-clinical first-in-human studies to regulatory submissions, health economics/outcomes research and market access value communication.
